Moleculin appoints Joy Yan, M.D., Ph.D. to Board of Directors

Moleculin Biotech, Inc.

Appointment effective March 1, 2022; Dr. Yan will serve as an independent director.
Compensation includes $40,000 annual cash retainer and 10-year option for 6,667 shares vesting over 3 years.
Dr. Yan brings experience from Bristol Myers Squibb, Janssen, Bayer; led development of nivolumab and ipilimumab.
No board committee assignments at this time.
Press release issued March 1, 2022; standard indemnification agreement executed.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Joy Yan

Independent Director

MBRX · Moleculin Biotech, Inc.

Effective: 2022-03-01
Filed: March 1, 2022, 6:59 PM ET

On March 1, 2022, the Board of Directors of Moleculin Biotech, Inc. (the “Company”) appointed Joy Yan as an independent member of the Company’s Board of Directors, effective on such date.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Joy Yan was appointed as Independent Director at Moleculin Biotech, Inc..

Action: appointed
Role: Independent Director

Exact text from the filing

On March 1, 2022, the Board of Directors of Moleculin Biotech, Inc. (the “Company”) appointed Joy Yan as an independent member of the Company’s Board of Directors, effective on such date.

View on SEC.gov

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-22-004769

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.